BRPI0512783A - composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto

Info

Publication number
BRPI0512783A
BRPI0512783A BRPI0512783-1A BRPI0512783A BRPI0512783A BR PI0512783 A BRPI0512783 A BR PI0512783A BR PI0512783 A BRPI0512783 A BR PI0512783A BR PI0512783 A BRPI0512783 A BR PI0512783A
Authority
BR
Brazil
Prior art keywords
mammal
inhibiting
treating
treat
inhibit
Prior art date
Application number
BRPI0512783-1A
Other languages
English (en)
Inventor
Christopher P Miller
Michael D Collini
Robert L Morris
Robert R Singhaus Jr
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0512783A publication Critical patent/BRPI0512783A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Abstract

COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, MéTODOS DE TRATAR OU INIBIR OSTEOPOROSE OU INIBIR A DESMINERALIZAçãO óSSEA EM UM MAMìFERO, DE TRATAR OU INIBIR DOENçAS EM UM MAMìFERO, DE DIMINUIR O COLESTEROL, TRIGLICERìDEOS, NìVEIS DE LP(A) OU LDL OU INIBIR DANO VASCULAR EM UM MAMìFERO, DE PROVER AUMENTO DA COGNIçãO OU NEUROPROTEçãO, DE TRATAR OU INIBIR ESTADOS DOENTIOS INDUZIDOS POR RADICAL LIVRE EM UM MAMìFERO, DE TRATAR OU INIBIR SINTOMAS VASOMOTORES EM UM MAMìFERO, DE CONTRACEPçãO EM UM MAMìFERO, DE TRATAR OU INIBIR DANO DE JUNTA SECUNDáRIO A PROCEDIMENTOS ARTROSCóPICOS OU CIRúRGICOS EM UM MAMìFERO E DE TRATAR OU INIBIR FERTILIDADE EM UM MAMìFERO, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA A PREPARAçAO DE UM COMPOSTO. Esta invenção provê moduladores do receptor do estrogênio, tendo a estrutura: (1) em que R~ 1~, R~ 2~, R~ 3~, R~ 4~, Q, n, R~ 8~, R~ 9~, R~ 10~ e R~ 11~ foram definidos na especificação; ou um sal farmaceuticamente aceitável do mesmo. A invenção provê ainda métodos para a preparação e uso dos compostos.
BRPI0512783-1A 2004-07-01 2005-06-29 composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto BRPI0512783A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58451604P 2004-07-01 2004-07-01
PCT/US2005/023044 WO2006007503A1 (en) 2004-07-01 2005-06-29 Tetracyclic compounds as estrogen ligands

Publications (1)

Publication Number Publication Date
BRPI0512783A true BRPI0512783A (pt) 2008-04-08

Family

ID=35170173

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512783-1A BRPI0512783A (pt) 2004-07-01 2005-06-29 composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto

Country Status (9)

Country Link
US (1) US20060004087A1 (pt)
EP (1) EP1761513A1 (pt)
JP (1) JP2008505095A (pt)
CN (1) CN1993343A (pt)
AU (1) AU2005262385A1 (pt)
BR (1) BRPI0512783A (pt)
CA (1) CA2570518A1 (pt)
MX (1) MXPA06015270A (pt)
WO (1) WO2006007503A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007347A (es) * 2004-12-17 2007-07-13 Wyeth Corp Usos nevodosos para agonistas de estrogeno beta.
DE102005056890A1 (de) * 2005-11-28 2007-05-31 Institut für Umweltmedizinische Forschung gGmbH Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut
CA2641116A1 (en) * 2006-02-14 2007-08-23 Wyeth Aqueous pharmaceutical formulations of er.beta. selective ligands
EP2035430A1 (en) * 2006-05-03 2009-03-18 Symrise GmbH & Co. KG 6h-benzofuro[3,2-c][1]benzopyran and [2]benzopyrano [4,3-b][1]benzopyran derivatives and wood extracts of these compounds as aryl hydrocarbon receptor (ahr) antagonists for the prevention of uv-b induced skin damage
CN100389123C (zh) * 2006-07-21 2008-05-21 中国科学院上海有机化学研究所 一类26-溴代-16,22-二氧代-胆甾醇化合物的合成方法
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
JP5484914B2 (ja) 2007-01-22 2014-05-07 ジーティーエックス・インコーポレイテッド 核内受容体結合剤
EP2048126A1 (de) * 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
CA2700210C (en) 2007-10-26 2015-12-22 Acadia Pharmaceuticals Inc. Condensed compounds with activity at estrogen receptors
ES2307462B1 (es) * 2008-06-30 2009-10-14 Fundacion Universitaria San Pablo Ceu (70%) Derivados de naftofurano y naftotiofeno como agentes antiproliferativos del cancer de pancreas y colon.
WO2010052734A1 (en) * 2008-11-06 2010-05-14 Council Of Scientific & Industrial Research Substituted benzfurochromenes and related compounds for the prevention and treatment of bone related disorders
RU2554937C1 (ru) * 2014-05-16 2015-07-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков им. Г.Ф. Гаузе" Российской академии медицинских наук (ФГБУ "НИИНА" РАМН) СПОСОБ ПОЛУЧЕНИЯ АНТРА[2,3-b]ФУРАН-3-КАРБОНОВОЙ КИСЛОТЫ
SG11202003827YA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Bridged bicyclic compounds as farnesoid x receptor modulators
CN115433200B (zh) * 2022-08-17 2023-07-21 广州大学 含苯并二氢吡喃-4-酮结构的四环化合物、合成方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4704400A (en) * 1986-06-24 1987-11-03 Merck & Co., Inc. Medicarpin derivatives and analogs
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
JP3050667B2 (ja) * 1991-09-18 2000-06-12 ライオン株式会社 抗男性ホルモン剤
US5399558A (en) * 1993-11-24 1995-03-21 Pathogenesis Corporation Isoflavonoid antibacterial compounds, compositions and use
US5721371A (en) * 1995-12-18 1998-02-24 Iowa State University Research Foundation, Inc. Synthesis of substituted pterocarpans
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6589980B2 (en) * 2001-05-17 2003-07-08 Wyeth Substituted 10,11-benzo[b]fluoren-10-ones as estrogenic agents
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6884814B2 (en) * 2001-12-13 2005-04-26 Wyeth Phenyl benzisoxazoles as estrogenic agents
US6914074B2 (en) * 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6960607B2 (en) * 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7157492B2 (en) * 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
KR20070061536A (ko) * 2004-09-07 2007-06-13 와이어쓰 ６Ｈ-[１]벤조피라노[４,３-ｂ]퀴놀린 및 에스트로겐제제로서의 이의 용도

Also Published As

Publication number Publication date
MXPA06015270A (es) 2007-03-15
US20060004087A1 (en) 2006-01-05
WO2006007503A1 (en) 2006-01-19
AU2005262385A1 (en) 2006-01-19
CN1993343A (zh) 2007-07-04
EP1761513A1 (en) 2007-03-14
JP2008505095A (ja) 2008-02-21
CA2570518A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
BRPI0512783A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto
BRPI0514628A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar ou inibir doenças, métodos para baixar os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl; ou inibir avaria da parede vascular, para prover aumento de cognição ou neuroproteção; para tratar ou inibir estados doentios induzidos por radical livre, condições, e inchação ou erosão de junta; ou tratar ou inibir avaria de junta secundária a procedimentos artroscópicos ou cirúrgicos, e, composição farmacêutica
BRPI0514974A (pt) composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto
Leigh et al. Radial head reconstruction versus replacement in the treatment of terrible triad injuries of the elbow
GRANOWITZ et al. The pathogenesis and long-term end results of pigmented villonodular synovitis
Howie et al. Cemented total hip arthroplasty with subtrochanteric osteotomy in dysplastic hips
Orbay et al. Multicenter trial of an internal joint stabilizer for the elbow
BR9814435A (pt) Novos esteróides antiestrogênicos e composições farmacêuticas associadas
BR0113200A (pt) Combinação terapêutica
Castricini et al. Shoulder hemiarthroplasty for fractures of the proximal humerus
Freeland et al. Stable fixation of the hand and wrist
BR0112364A (pt) Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios
Pietsch et al. Treatment of deep infection of total knee arthroplasty using a two-stage procedure
Jagodzinski et al. Arthroscopic triple and modified double hindfoot arthrodesis
Ansari et al. Management of type 13C2 distal humerus fractures by olecranon osteotomy approach versus triceps sparing approach—our experience with sixty cases
Nagata et al. The management of secondary frozen shoulder after anterior shoulder dislocation–the results of manipulation under anaesthesia and injection
Marcuzzi et al. Chronic transscaphoid, transcapitate perilunate fracture dislocation of the wrist: Fenton's syndrome
Salazar et al. Unique indications for internal joint stabilizer for elbow instability
Bach et al. Disability can be avoided after open fractures in Africa—results from Malawi
Bennett et al. Total elbow arthroplasty: surgical technique
Guo et al. Polylactide pins can effectively fix severely comminuted and unsalvageable radial head fracture: a retrospective study of 40 patients
Keen Before and after Lister
Obeid et al. Percutaneous fixation of Maisonneuve and Maisonneuve-type fractures: a minimally invasive approach
Munshi et al. Does Panchatikta ghrita have anti-osteoporotic effect? Assessment in an experimental model in ovariectomized rats
BR0212824A (pt) Composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.